Your session is about to expire
← Back to Search
JNJ-78278343 for Prostate Cancer
Study Summary
This trial is testing a new drug to see what dose is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an ongoing hepatitis B or C infection.I have had a solid organ or bone marrow transplant.I have not been diagnosed with any cancer other than prostate cancer in the last 2 years.I am HIV positive but my viral load is undetectable due to stable antiretroviral therapy.I am fully active or can carry out light work.I have not taken any cancer treatments for at least 2 weeks.My prostate cancer has spread to other parts of my body.My cancer can be measured or seen on tests.I haven't had major blood clotting issues in the last month.I have taken immune-suppressing drugs within the last 3 days.I haven't had an autoimmune disease flare-up in the last year.I currently have an infection.I do not have any health issues that would prevent me from receiving the planned treatment.My cancer has spread to my brain or spinal cord.I have had my testicles removed or am on hormone therapy for cancer.I have been treated with a therapy targeting KLK2 before.I have had treatment with a specific hormone therapy or chemotherapy before.I have not had, nor plan to have, any live vaccines 4 weeks before starting the study drug.I haven't had major heart or blood vessel diseases in the last 6 months.I have a serious lung condition.I am still experiencing side effects from previous cancer treatments.
- Group 1: JNJ-78278343
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment currently open for participation in this trial?
"As reported on clinicaltrials.gov, this research endeavour is in the process of sourcing participants. It was posted initially on July 13th 2021 and recently updated on November 22nd 2022."
What ultimate effects are investigators hoping to observe with this clinical investigation?
"The principal purpose of this prolonged (over one year and ten months) clinical trial is to determine the occurrence rate of dose-limiting toxicity. Secondary objectives involve measuring serum concentrations of anti-JNJ78278343 antibodies, prostate specific antigen levels, as well as calculating PSA response rates by evaluating any decline from baseline values that are greater than 50%."
How many participants have been recruited for this experiment?
"Affirmative. According to the clinicaltrials.gov, this medical study is actively recruiting subjects that meet the criteria it posted on July 13 2021 and updated on November 22 2022. The research project requires 110 patients from 3 sites for its completion."
What potential risks are posed by JNJ-78278343?
"Due to the limited supporting evidence for JNJ-78278343's efficacy and safety, our team at Power judged it a score 1 on the scale of 1 to 3."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger